Neuroimmunology and Neuroinflammation
Acquired myasthenia gravis (MG) is a protoypical autoimmune disease caused by a dysfunction of neuromuscular transmission at the postsynaptic part.
Patients experience fluctuating muscle weakness that increases with exertion. It is typically classified into clinical subtypes depending on distribution of involved muscles, onset age, thymic pathology, and auto-antibodies. While the most common autoantibodies are targeted towards the skeletal muscle acetylcholine receptor (AChR), the list of target molecules of pathogenic auto-antibodies has been expanding to include the muscle specific tyrosine kinase (MuSK), low-density lipoprotein receptorrelated protein 4 and agrin. [1] [2] [3] [4] [5] MuSK MG in particular has been of great interest. It is clinically characterized by bulbar predominant manifestation, marked atrophy of the involved facial muscle, frequent myathenic crisis, poor outcome with conventional immunosuppressants, intolerance to acetylcholinesterase inhibitors, and fewer thymic pathologic changes. [6] The disease is also known for its unique immunological features. The pathogenic autoantibodies are mainly immunoglobulin G4 (IgG4), [7] which unlike the IgG subtypes in AChR MG (IgG1 and IgG3) does not activate the complements and effector cells. Little is known about the precise cellular components and molecular mechanisms in MuSK MG.
Guptill et al. [8] have recently reported the characteristics of B lymphocytes in MuSK MG patients. They performed polychromatic flow cytometry and enzymelinked immuno sorbent assays in peripheral blood samples from MuSK MG patients, and compared immunological features of the patients to those of healthy controls. They found no differences in the frequencies of total B cells and B cell subsets (naive, memory, class-switched, plasmablasts and transitional cells) between the healthy controls and MuSK MG patients who had not been treated with rituximab (anti-CD20 monoclonal antibody). There was no difference between immunosuppressed and non-immunosuppressed patients either. However, the plasma B-cell activating factor (BAFF) levels were significantly increased in MuSK MG patients; another main finding of this study is that in vitro stimulation of peripheral blood mononuclear cells resulted in lower percentages of B10 cells in MuSK MG patients compared to controls.
Despite the limitations of small number of patients and heterogeneous treatments, this study provides novel insights and understanding of the immunopathology of MuSK MG. First, this study supports the emerging pathogenic role of BAFF which is a cytokine essential for the survival and differentiation of B cells. A clinical trial of belimumab, the monoclonal antibody that targets BAFF, is currently in progress for MG patients. It will be interesting to see if the drug is effective for MuSK MG which is often refractory to conventional immunosuppressive treatment. Second, B10 cells are recently characterized regulatory subset of B cells producing IL-10. With no change in Treg frequency and function, the reduced B10 cells observed in this study suggests a potential mechanism of breakdown in the immune tolerance in MuSK MG. [9] Future studies of larger number of patients would help further elucidate the precise immunobiology of this rare autoimmune disease.
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